loading
전일 마감가:
$2.88
열려 있는:
$2.9
하루 거래량:
198.74K
Relative Volume:
0.05
시가총액:
$156.55M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
290.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
-1.36%
1개월 성능:
+316.49%
6개월 성능:
+209.33%
1년 성능:
+118.05%
1일 변동 폭
Value
$2.90
$2.91
1주일 범위
Value
$2.81
$3.02
52주 변동 폭
Value
$0.5052
$3.06

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name
명칭
Spero Therapeutics Inc
Name
전화
857-242-1600
Name
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Name
직원
32
Name
트위터
@spero_tx
Name
다음 수익 날짜
2025-03-19
Name
최신 SEC 제출 서류
Name
SPRO's Discussions on Twitter

SPRO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SPRO
Spero Therapeutics Inc
2.90 156.55M 76.19M -1.61M 28.98M 0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.76 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.26 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.59 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.80 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.65 28.51B 3.81B -644.79M -669.77M -6.24

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-20 다운그레이드 Evercore ISI Outperform → In-line
2022-09-23 업그레이드 Evercore ISI In-line → Outperform
2021-10-01 다운그레이드 Oppenheimer Outperform → Perform
2021-01-22 재확인 H.C. Wainwright Buy
2020-12-16 개시 Berenberg Buy
2020-09-29 개시 Evercore ISI Outperform
2019-11-05 재확인 H.C. Wainwright Buy
2019-09-09 개시 Janney Buy
2018-02-09 개시 Cantor Fitzgerald Overweight
2017-11-27 개시 BofA/Merrill Neutral
2017-11-27 개시 Oppenheimer Outperform
2017-11-27 개시 Stifel Buy
모두보기

Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스

pulisher
Jun 17, 2025

Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 12, 2025

SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister

Jun 06, 2025
pulisher
Jun 06, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 04, 2025
pulisher
May 31, 2025

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN

May 30, 2025
pulisher
May 30, 2025

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN

May 30, 2025
pulisher
May 29, 2025

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter

May 29, 2025
pulisher
May 28, 2025

Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News

May 28, 2025
pulisher
May 28, 2025

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga

May 28, 2025
pulisher
May 28, 2025

GSK, Spero stop UTI drug trial after early success - Reuters

May 28, 2025
pulisher
May 28, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance

May 28, 2025
pulisher
May 17, 2025

Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World

May 17, 2025
pulisher
May 15, 2025

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan

May 13, 2025
pulisher
May 13, 2025

SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus

May 13, 2025
pulisher
May 07, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World

May 07, 2025
pulisher
May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times

May 05, 2025
pulisher
May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune

May 05, 2025
pulisher
May 03, 2025

SPROSpero Therapeuti Latest Stock News & Market Updates - Stock Titan

May 03, 2025
pulisher
Apr 30, 2025

Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 30, 2025

Spero Therapeutics Inc (SPRO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Spero Therapeutics Inc 주식 (SPRO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Rajavelu Esther
CFO & CBO
Feb 05 '25
Sale
0.78
20,689
16,137
724,720
Shukla Sath
CEO & President
Feb 05 '25
Sale
0.78
155,333
121,160
1,736,883
Mahadevia Ankit
Director
Feb 05 '25
Sale
0.78
69,219
53,991
689,866
Rajavelu Esther
CFO & CBO
Nov 07 '24
Sale
1.31
23,351
30,590
396,515
Rajavelu Esther
CFO & CBO
Nov 08 '24
Sale
1.30
17,245
22,418
379,270
Mahadevia Ankit
Director
Aug 27 '24
Sale
1.35
5,912
7,981
759,085
Keutzer Timothy
Chief Operating Officer
Aug 27 '24
Sale
1.35
2,213
2,988
531,837
Shukla Sath
CEO & President
Aug 27 '24
Sale
1.35
2,757
3,722
1,140,809
Shukla Sath
CEO and President
Aug 05 '24
Sale
1.31
17,641
23,110
1,143,566
Shukla Sath
CEO and President
Aug 02 '24
Sale
1.32
14,800
19,536
1,161,207
$20.44
price down icon 1.54%
$35.82
price down icon 1.12%
$20.61
price down icon 1.39%
$105.15
price down icon 0.66%
$103.92
price down icon 1.26%
biotechnology ONC
$266.62
price down icon 0.13%
자본화:     |  볼륨(24시간):